PDF(Pubmed)
Abstract：
BACKGROUND: Glucagon-like peptide-1 (GLP-1) plays a crucial role in metabolic disorders by enhancing insulin secretion, inhibiting glucagon release, and slowing gastric emptying, thereby improving glycemic control. In recent years, GLP-1 role in neuronal pathways has expanded its therapeutic potential. We aim to comprehensively evaluate the relevance of GLP-1 in headache and pain disorders.
METHODS: A systematic literature search was conducted on PubMed and Embase (Ovid) databases using the search terms \"GLP-1\" and \"pain\". Animal and human studies published in English language were included. Abstracts, reviews, and articles on other disorders than \"pain\" were excluded.
RESULTS: The search strategy identified 833 hits, of which 42 studies were included in the final review. The studies were categorized into four groups: inflammatory pain and osteoarthritis, headaches, neuropathic pain and diabetic neuropathy, and visceral pain and irritable bowel syndrome. GLP-1 receptor (GLP-1R) agonists, like liraglutide, have shown analgesic effects by modulating pain hypersensitivity in animal models of inflammatory and neuropathic pain. GLP-1 is involved in migraine mechanisms and GLP-1R agonists are beneficial in individuals with idiopathic intracranial hypertension. Additionally, GLP-1R agonists reduce visceral hypersensitivity and ameliorate symptoms in patients with irritable bowel syndrome.
CONCLUSIONS: The therapeutic scope of GLP-1R agonists is expanding beyond traditional metabolic targets, highlighting its potential for headache and pain disorders. Engineering bimodal molecules that integrate GLP-1R agonism with specific pain-related mechanisms may offer innovative therapeutic options.
METHODS: A systematic literature search was conducted on PubMed and Embase (Ovid) databases using the search terms \"GLP-1\" and \"pain\". Animal and human studies published in English language were included. Abstracts, reviews, and articles on other disorders than \"pain\" were excluded.
RESULTS: The search strategy identified 833 hits, of which 42 studies were included in the final review. The studies were categorized into four groups: inflammatory pain and osteoarthritis, headaches, neuropathic pain and diabetic neuropathy, and visceral pain and irritable bowel syndrome. GLP-1 receptor (GLP-1R) agonists, like liraglutide, have shown analgesic effects by modulating pain hypersensitivity in animal models of inflammatory and neuropathic pain. GLP-1 is involved in migraine mechanisms and GLP-1R agonists are beneficial in individuals with idiopathic intracranial hypertension. Additionally, GLP-1R agonists reduce visceral hypersensitivity and ameliorate symptoms in patients with irritable bowel syndrome.
CONCLUSIONS: The therapeutic scope of GLP-1R agonists is expanding beyond traditional metabolic targets, highlighting its potential for headache and pain disorders. Engineering bimodal molecules that integrate GLP-1R agonism with specific pain-related mechanisms may offer innovative therapeutic options.
摘要：
背景：胰高血糖素样肽-1（GLP-1）通过增强胰岛素分泌在代谢紊乱中起关键作用，抑制胰高血糖素释放，减缓胃排空，从而改善血糖控制。近年来,GLP-1在神经元途径中的作用扩大了其治疗潜力。我们旨在全面评估GLP-1在头痛和疼痛障碍中的相关性。
方法：在PubMed和Embase(Ovid)数据库中使用检索词“GLP-1”和“疼痛”进行系统的文献检索。包括以英语发表的动物和人类研究。摘要,reviews,以及“疼痛”以外的其他疾病的文章被排除在外。
结果：搜索策略确定了833个命中，其中42项研究被纳入最终审查.这些研究分为四组：炎性疼痛和骨关节炎，头痛,神经性疼痛和糖尿病性神经病,内脏疼痛和肠易激综合征.GLP-1受体（GLP-1R）激动剂，比如利拉鲁肽,在炎症和神经性疼痛的动物模型中通过调节疼痛超敏反应显示出镇痛作用。GLP-1参与偏头痛机制，GLP-1R激动剂对特发性颅内高压患者有益。此外,GLP-1R激动剂降低肠易激综合征患者的内脏高敏感性并改善症状.
结论：GLP-1R激动剂的治疗范围正在超越传统的代谢靶点，强调其头痛和疼痛障碍的潜力。将GLP-1R激动作用与特定疼痛相关机制整合的工程双峰分子可以提供创新的治疗选择。
方法：在PubMed和Embase(Ovid)数据库中使用检索词“GLP-1”和“疼痛”进行系统的文献检索。包括以英语发表的动物和人类研究。摘要,reviews,以及“疼痛”以外的其他疾病的文章被排除在外。
结果：搜索策略确定了833个命中，其中42项研究被纳入最终审查.这些研究分为四组：炎性疼痛和骨关节炎，头痛,神经性疼痛和糖尿病性神经病,内脏疼痛和肠易激综合征.GLP-1受体（GLP-1R）激动剂，比如利拉鲁肽,在炎症和神经性疼痛的动物模型中通过调节疼痛超敏反应显示出镇痛作用。GLP-1参与偏头痛机制，GLP-1R激动剂对特发性颅内高压患者有益。此外,GLP-1R激动剂降低肠易激综合征患者的内脏高敏感性并改善症状.
结论：GLP-1R激动剂的治疗范围正在超越传统的代谢靶点，强调其头痛和疼痛障碍的潜力。将GLP-1R激动作用与特定疼痛相关机制整合的工程双峰分子可以提供创新的治疗选择。
